St. Jude Medical, a global healthcare technologies manufacturer based in Little Canada, Minnesota, announced that the company’s updated cardiac resynchronization therapy defibrillators and Assuras ICDs received CE Mark approval from the European Union.
The newly-updated cardiac devices include upgraded algorithms to minimize the risk of unnecessary shocks. At the same time, the devices are able to maintain high peak levels of delivered energy for patients in cardiac arrest.
The new Assura suit of products includes the Fortify Assura ICD, the Unify Assura CRT-D and the Quadra Assura CRT-D. All the cardiac rhythm management systems feature the company’s proprietary Shockguard technology. With Shockguard, healthcare providers can minimize the risk of unnecessary or inappropriate shocks. Since inappropriate shocks are unpleasant for a patient, patients using an over-sensitive unit may not use it when needed. St. Jude Medical also received approval for the newly-updated Assura products from the United States Food and Drug Administration.
Eric Fain is the president of St. Jude Medical’s cardiac rhythm management division. In prepared remarks, he stated, "For some patients, the fear of receiving a shock can either prevent them from receiving a potentially life-saving device, or cause anxiety that reduces their quality of life once they receive the device.” He continued, "These devices directly address this patient concern and provides physicians additional tools to manage individual patient needs."
- Medical Devices Come Home: How to Address the Challenges - Supplier Resource
- Eliminating Adhesives in Medical Tubing Assemblies - Supplier Resource
- SABEU Portfolio - Supplier Resource
- Can Your Contractor Really Support Your Product's Full Lifecycle? - Supplier Resource
- What’s the Point? Meeting Evolving Challenges in Consumer-Driven Healthcare - Webcast
- Innovative Solutions for Imaging and Telemedicine - Supplier Resource